Ajjai Shivaram Alva
University of Michigan · 456 works · 17,608 citations · h-index 60
Top works
- Regulation of an ATG7 - beclin 1 Program of Autophagic Cell Death by Caspase-8
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Integrative clinical genomics of metastatic cancer
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
- A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
- Autophagy in human tumors: cell survival or death?
- Bladder Cancer Treatment Response Assessment in CT using Radiomics with Deep-Learning
- Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
- Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
- Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response